Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.42 |
| ▸ | HPGDS | O60760 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29950578 | 1.00 | MGLL (0.54) | MGLLCA1CA2LDHABAZ2B | |
| SCHEMBL28718108 | 0.84 | MGLL (0.46) | MGLLCA1CA2LDHABAZ2B | |
| SCHEMBL38656446 | 0.83 | ENPP2 (0.42) | MGLLCA1CA2CA4CA6 | |
| SCHEMBL26314552 | 0.83 | ENPP2 (0.42) | MGLLCA1CA2CA4CA6 | |
| SCHEMBL25192631 | 0.82 | CYP2A6 (0.57) | CYP11B1CYP11B2 | |
| SCHEMBL30376699 | 0.82 | CYP2A6 (0.57) | CYP11B1CYP11B2 | |
| SCHEMBL2560337 | 0.81 | NPC1 (0.53) | MGLLCA1CA2CYP11B1CYP11B2 | |
| SCHEMBL30518373 | 0.81 | NPC1 (0.53) | MGLLCA1CA2CYP11B1CYP11B2 | |
| SCHEMBL14668828 | 0.81 | CA2 (0.54) | MGLLCA1CA2 | |
| SCHEMBL19780935 | 0.81 | ENPP2 (0.54) | MGLLCA1CA2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114249685-A | Ortho-diaryl substituted phenanthrene or phenanthroline carrier transport material and preparation method and application thereof | 华南理工大学 | 2022-03-29 | — | — | CN | claimed |
| US-20260078104-A1 | ORGANIC LIGHT-EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2026-03-19 | — | — | US | disclosed |
| US-12545656-B2 | Organic light-emitting compound and organic electroluminescent device using the same | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2026-02-10 | — | — | US | disclosed |
| US-20260040756-A1 | Compound, Organic Semiconducting Material Comprising the Same, Organic Electronic Device Comprising the Same and Display Device Comprising the Same | NOVALED GMBH (DE) | 2026-02-05 | — | — | US | disclosed |
| CN-119698411-A | Compound, organic semiconductor material comprising the same, organic electronic device comprising the same, and display device comprising the same | 诺瓦尔德股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119591542-A | ADAR1 small molecule inhibitor, pharmaceutical composition and application thereof | 深圳市新樾生物科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025009539-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | 出光興産株式会社 | 2025-01-09 | — | — | WO | disclosed |
| EP-4472956-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-10 | — | — | US | disclosed |
| CN-118702627-A | CD73 small molecule inhibitor, pharmaceutical composition and application thereof | 深圳市新樾生物科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20110288295-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110288295-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2361909-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | Tosoh Corporation (JP) | 2011-08-31 | — | — | EP | disclosed |
| EP-2361909-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | Tosoh Corporation (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-20110124808-A1 | POLYMERIC COMPOUND CONTAINING METAL COMPLEX RESIDUE AND ELEMENT COMPRISING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124808-A1 | POLYMERIC COMPOUND CONTAINING METAL COMPLEX RESIDUE AND ELEMENT COMPRISING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010118029-A1 | METAL COMPLEX COMPRISING NOVEL LIGAND STRUCTURES | UNIVERSAL DISPLAY CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118029-A1 | METAL COMPLEX COMPRISING NOVEL LIGAND STRUCTURES | UNIVERSAL DISPLAY CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-0541081-B1 | Compounds with only a side chain for use in liquid crystal mixtures | AVENTIS RES & TECH GMBH & CO (DE) | 2002-04-10 | — | — | EP | disclosed |
| US-5849216-A | Compounds for use in liquid-crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288295-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | VDAC1, MT-ND5, TRPC5 | MGLL 4044/4885CA1 3389/4885CA2 1991/4885 |
| US-20110124808-A1 | POLYMERIC COMPOUND CONTAINING METAL COMPLEX RESIDUE AND ELEMENT COMPRISING SAME | ZRANB2, ZKSCAN2, SLC39A3 | MGLL 4032/4885CA1 309/4885CA2 668/4885 |
| US-12545656-B2 | Organic light-emitting compound and organic electroluminescent device using the same | ELOVL1, EPB41L2, L1CAM | MGLL 2758/4885CA1 3308/4885CA2 3094/4885 |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | PTPN2, PTPN22, PTPN5 | MGLL 515/4885CA1 4536/4885CA2 1627/4885 |
| US-20260040756-A1 | Compound, Organic Semiconducting Material Comprising the Same, Organic Electronic Device Comprising the Same and Display Device Comprising the Same | OR10J3, CCR1, CCR6 | MGLL 1132/4885CA1 3807/4885CA2 3541/4885 |
| US-20260078104-A1 | ORGANIC LIGHT-EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | ELOC, ELOVL1, EMC1 | MGLL 1304/4885CA1 1997/4885CA2 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.